Oct 23, 2026 · Scheduled
BESTOW kidney-transplant presentation
4:40–4:50 PM MDT · ASN Kidney Week
Patient-reported outcomes from the Phase 2 trial compare tegoprubart with tacrolimus in kidney-transplant recipients.
Original source ↗Nasdaq
ELDN Research Hub
Eledon Pharmaceuticals, Inc.
Latest signal
S-8 filed 2026-09-04
S-8
PennyIntel health score
7.0/10
Higher is healthier / lower risk. Constructive
What to watch next
Newest source: S-8. Useful checks are financing terms, proxy votes, ownership changes, compliance notices, and material-event language.
Dates to watch
Upcoming catalysts
Showing the latest available coverage. No matching headlines from the past 48 hours were found.
News pulse
Latest related coverage
Coverage is quiet. Keep SEC filings, ownership changes, and discussion alerts active.
Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubart Trial Data and FDA Fast Track
On September 22, 2026, Eledon Pharmaceuticals Inc (NASDAQ: ELDN) experienced a notable uptick in its stock price following the release of promising long-term re
On September 22, 2026, Eledon
Compliance
FDA/clinical
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22
2026-09-22. The following slide deck was published by Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22
Compliance
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ)
Eledon Pharmaceuticals (ELDN) stock gains as the firm posts new mid-stage trial data for its lead asset and wins FDA fast-track status for the drug. Read more here.
Compliance
FDA/clinical
Premarket/momentum
Ticker coverage
Read source
Eledon Pharmaceuticals (ELDN) Advances Tegoprubart Trials with FDA Fast Track Designation
On September 22, 2026, Eledon Pharmaceuticals Inc (NASDAQ: ELDN) announced significant progress in its development of tegoprubart, an immunomodulatory drug aime
On September 22, 2026, Eledon
Compliance
FDA/clinical
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN)
Eledon Pharmaceuticals (ELDN) is rated Buy, with tegoprubart showing strong promise post-Phase 2 in kidney transplantation and significant undervaluation...
Eledon Pharmaceuticals[+169 characters]
Compliance
FDA/clinical
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22
2026-06-22. The following slide deck was published by Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22
Compliance
FDA/clinical
Community pulse
ELDN trader notes
No trader notes yet for ELDN. Be first to add a filing note, catalyst watch, or risk warning.
Checking account...
Alert signals
Signals worth watching
Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubart Trial Data and FDA Fast Track
On September 22, 2026, Eledon Pharmaceuticals Inc (NASDAQ: ELDN) experienced a notable uptick in its stock price following the release of promising long-term re
S-8 filed 2026-09-04
S-8
Dilution safety at 6/10
This is the weakest current PennyIntel check. Put alerts on financing, proxy, compliance, and ownership changes before treating the setup as clean.
4 · 2026-08-04
Insider ownership filing detected. Check the ownership panel for transaction detail and cross-check links.
What should trigger a follow-up
Newest source: S-8. Useful checks are financing terms, proxy votes, ownership changes, compliance notices, and material-event language.
Follow this ticker to track news, SEC changes, ownership activity, catalysts, risk moves, and active discussion in one place.
Filings worth checking
No recent split/proxy filing was flagged in the latest SEC feed. Start with the latest filings below for verified source context.